A randomized control trial of the impact of LCPUFA-ω3 supplementation on body weight and insulin resistance in pubertal children with obesity

M. López-Alarcón, P. Inda-Icaza, M. C. Márquez-Maldonado, A. Armenta-Álvarez, L. Barbosa-Cortés, J. Maldonado-Hernández, M. Piña-Aguero, A. Barradas-Vázquez, B. A. Núñez-García, M. Rodríguez-Cruz, J. R. Fernández

Resultado de la investigación: Contribución a una revistaArtículo

1 Cita (Scopus)

Resumen

Background: Paediatric obesity and insulin resistance (IR) are potentially reversible inflammatory conditions. Long chain polyunsaturated fatty acids omega-3 (LCPUFA-ω3) show anti-inflammatory and metabolic properties, but their clinical efficacy is unclear. Objective: The objective of this study is to evaluate whether supplementation with LCPUFA-ω3 for 3 months reduces insulin resistance and weight to adolescents with obesity. Methods: Double-blind trial of 366 adolescents with obesity randomly assigned to 1.2-g LCPUFA-ω3 (DO3) or 1-g sunflower oil (DP) daily for 3 months; both groups received an energy-restricted diet. Children attended monthly for anthropometric, dietary, and clinical measurements. Basal and final blood samples were obtained to measure metabolic markers and erythrocytes fatty acids. Regression models were used for analysis. Results: A total of 119 DO3 and 126 DP children completed follow-up. At baseline, 92% of children presented IR, 66% hypertriglyceridemia, 37% low-grade inflammation, and 32% metabolic syndrome. Despite erythrocytes LCPUFA-ω3 increased more in DO3 (Median differences = 0.984 w/w%; 95 IC = 0.47, 1.53, P < 0.001), body weight, insulin, and HOMA changed similarly in both groups at the end of intervention. Adjusting for basal values, changes in weight, insulin, and HOMA was not related with supplementation. Conclusions: Supplementation with LCPUFA-ω3 does not affect body weight or insulin in adolescents with obesity.

Idioma originalInglés
Número de artículoe12499
PublicaciónPediatric Obesity
Volumen14
N.º5
DOI
EstadoPublicada - may 2019

Huella dactilar

Pediatric Obesity
Unsaturated Fatty Acids
Insulin Resistance
Body Weight
Insulin
Erythrocytes
Weights and Measures
Hypertriglyceridemia
Double-Blind Method
Anti-Inflammatory Agents
Fatty Acids
Diet
Inflammation

Citar esto

López-Alarcón, M., Inda-Icaza, P., Márquez-Maldonado, M. C., Armenta-Álvarez, A., Barbosa-Cortés, L., Maldonado-Hernández, J., ... Fernández, J. R. (2019). A randomized control trial of the impact of LCPUFA-ω3 supplementation on body weight and insulin resistance in pubertal children with obesity. Pediatric Obesity, 14(5), [e12499]. https://doi.org/10.1111/ijpo.12499
López-Alarcón, M. ; Inda-Icaza, P. ; Márquez-Maldonado, M. C. ; Armenta-Álvarez, A. ; Barbosa-Cortés, L. ; Maldonado-Hernández, J. ; Piña-Aguero, M. ; Barradas-Vázquez, A. ; Núñez-García, B. A. ; Rodríguez-Cruz, M. ; Fernández, J. R. / A randomized control trial of the impact of LCPUFA-ω3 supplementation on body weight and insulin resistance in pubertal children with obesity. En: Pediatric Obesity. 2019 ; Vol. 14, N.º 5.
@article{7c77f0a7f80c4b53b1e5164b05061ee3,
title = "A randomized control trial of the impact of LCPUFA-ω3 supplementation on body weight and insulin resistance in pubertal children with obesity",
abstract = "Background: Paediatric obesity and insulin resistance (IR) are potentially reversible inflammatory conditions. Long chain polyunsaturated fatty acids omega-3 (LCPUFA-ω3) show anti-inflammatory and metabolic properties, but their clinical efficacy is unclear. Objective: The objective of this study is to evaluate whether supplementation with LCPUFA-ω3 for 3 months reduces insulin resistance and weight to adolescents with obesity. Methods: Double-blind trial of 366 adolescents with obesity randomly assigned to 1.2-g LCPUFA-ω3 (DO3) or 1-g sunflower oil (DP) daily for 3 months; both groups received an energy-restricted diet. Children attended monthly for anthropometric, dietary, and clinical measurements. Basal and final blood samples were obtained to measure metabolic markers and erythrocytes fatty acids. Regression models were used for analysis. Results: A total of 119 DO3 and 126 DP children completed follow-up. At baseline, 92{\%} of children presented IR, 66{\%} hypertriglyceridemia, 37{\%} low-grade inflammation, and 32{\%} metabolic syndrome. Despite erythrocytes LCPUFA-ω3 increased more in DO3 (Median differences = 0.984 w/w{\%}; 95 IC = 0.47, 1.53, P < 0.001), body weight, insulin, and HOMA changed similarly in both groups at the end of intervention. Adjusting for basal values, changes in weight, insulin, and HOMA was not related with supplementation. Conclusions: Supplementation with LCPUFA-ω3 does not affect body weight or insulin in adolescents with obesity.",
keywords = "DHA, EPA, LCPUFA-ω3, bodyweight, insulin resistance",
author = "M. L{\'o}pez-Alarc{\'o}n and P. Inda-Icaza and M{\'a}rquez-Maldonado, {M. C.} and A. Armenta-{\'A}lvarez and L. Barbosa-Cort{\'e}s and J. Maldonado-Hern{\'a}ndez and M. Pi{\~n}a-Aguero and A. Barradas-V{\'a}zquez and N{\'u}{\~n}ez-Garc{\'i}a, {B. A.} and M. Rodr{\'i}guez-Cruz and Fern{\'a}ndez, {J. R.}",
year = "2019",
month = "5",
doi = "10.1111/ijpo.12499",
language = "Ingl{\'e}s",
volume = "14",
journal = "Pediatric obesity",
issn = "2047-6302",
publisher = "Wiley-Blackwell for the International Association for the Study of Obesity",
number = "5",

}

López-Alarcón, M, Inda-Icaza, P, Márquez-Maldonado, MC, Armenta-Álvarez, A, Barbosa-Cortés, L, Maldonado-Hernández, J, Piña-Aguero, M, Barradas-Vázquez, A, Núñez-García, BA, Rodríguez-Cruz, M & Fernández, JR 2019, 'A randomized control trial of the impact of LCPUFA-ω3 supplementation on body weight and insulin resistance in pubertal children with obesity', Pediatric Obesity, vol. 14, n.º 5, e12499. https://doi.org/10.1111/ijpo.12499

A randomized control trial of the impact of LCPUFA-ω3 supplementation on body weight and insulin resistance in pubertal children with obesity. / López-Alarcón, M.; Inda-Icaza, P.; Márquez-Maldonado, M. C.; Armenta-Álvarez, A.; Barbosa-Cortés, L.; Maldonado-Hernández, J.; Piña-Aguero, M.; Barradas-Vázquez, A.; Núñez-García, B. A.; Rodríguez-Cruz, M.; Fernández, J. R.

En: Pediatric Obesity, Vol. 14, N.º 5, e12499, 05.2019.

Resultado de la investigación: Contribución a una revistaArtículo

TY - JOUR

T1 - A randomized control trial of the impact of LCPUFA-ω3 supplementation on body weight and insulin resistance in pubertal children with obesity

AU - López-Alarcón, M.

AU - Inda-Icaza, P.

AU - Márquez-Maldonado, M. C.

AU - Armenta-Álvarez, A.

AU - Barbosa-Cortés, L.

AU - Maldonado-Hernández, J.

AU - Piña-Aguero, M.

AU - Barradas-Vázquez, A.

AU - Núñez-García, B. A.

AU - Rodríguez-Cruz, M.

AU - Fernández, J. R.

PY - 2019/5

Y1 - 2019/5

N2 - Background: Paediatric obesity and insulin resistance (IR) are potentially reversible inflammatory conditions. Long chain polyunsaturated fatty acids omega-3 (LCPUFA-ω3) show anti-inflammatory and metabolic properties, but their clinical efficacy is unclear. Objective: The objective of this study is to evaluate whether supplementation with LCPUFA-ω3 for 3 months reduces insulin resistance and weight to adolescents with obesity. Methods: Double-blind trial of 366 adolescents with obesity randomly assigned to 1.2-g LCPUFA-ω3 (DO3) or 1-g sunflower oil (DP) daily for 3 months; both groups received an energy-restricted diet. Children attended monthly for anthropometric, dietary, and clinical measurements. Basal and final blood samples were obtained to measure metabolic markers and erythrocytes fatty acids. Regression models were used for analysis. Results: A total of 119 DO3 and 126 DP children completed follow-up. At baseline, 92% of children presented IR, 66% hypertriglyceridemia, 37% low-grade inflammation, and 32% metabolic syndrome. Despite erythrocytes LCPUFA-ω3 increased more in DO3 (Median differences = 0.984 w/w%; 95 IC = 0.47, 1.53, P < 0.001), body weight, insulin, and HOMA changed similarly in both groups at the end of intervention. Adjusting for basal values, changes in weight, insulin, and HOMA was not related with supplementation. Conclusions: Supplementation with LCPUFA-ω3 does not affect body weight or insulin in adolescents with obesity.

AB - Background: Paediatric obesity and insulin resistance (IR) are potentially reversible inflammatory conditions. Long chain polyunsaturated fatty acids omega-3 (LCPUFA-ω3) show anti-inflammatory and metabolic properties, but their clinical efficacy is unclear. Objective: The objective of this study is to evaluate whether supplementation with LCPUFA-ω3 for 3 months reduces insulin resistance and weight to adolescents with obesity. Methods: Double-blind trial of 366 adolescents with obesity randomly assigned to 1.2-g LCPUFA-ω3 (DO3) or 1-g sunflower oil (DP) daily for 3 months; both groups received an energy-restricted diet. Children attended monthly for anthropometric, dietary, and clinical measurements. Basal and final blood samples were obtained to measure metabolic markers and erythrocytes fatty acids. Regression models were used for analysis. Results: A total of 119 DO3 and 126 DP children completed follow-up. At baseline, 92% of children presented IR, 66% hypertriglyceridemia, 37% low-grade inflammation, and 32% metabolic syndrome. Despite erythrocytes LCPUFA-ω3 increased more in DO3 (Median differences = 0.984 w/w%; 95 IC = 0.47, 1.53, P < 0.001), body weight, insulin, and HOMA changed similarly in both groups at the end of intervention. Adjusting for basal values, changes in weight, insulin, and HOMA was not related with supplementation. Conclusions: Supplementation with LCPUFA-ω3 does not affect body weight or insulin in adolescents with obesity.

KW - DHA

KW - EPA

KW - LCPUFA-ω3

KW - bodyweight

KW - insulin resistance

UR - http://www.scopus.com/inward/record.url?scp=85059153214&partnerID=8YFLogxK

U2 - 10.1111/ijpo.12499

DO - 10.1111/ijpo.12499

M3 - Artículo

AN - SCOPUS:85059153214

VL - 14

JO - Pediatric obesity

JF - Pediatric obesity

SN - 2047-6302

IS - 5

M1 - e12499

ER -